Three high-spin tetranuclear cobalt(II) complexes have been prepared with the bridging ligand 4,7-phenanthrolino-5,6:5',6'-pyrazine (ppz) through metal-ion directed self-assembly. The complexes differ by the incorporation of three different coordinating anions: chloride, thiocyanide and selenocyanide. The physical properties of these complexes have been investigated in detail.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c1dt11254f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dissecting the Binding Affinity of Anti-SARS-CoV-2 Compounds to Human Transmembrane Protease, Serine 2: A Computational Study.
Int J Mol Sci
January 2025
State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan and School of Life Sciences, Yunnan University, Kunming 650091, China.
The human transmembrane protease, serine 2 (TMPRSS2), essential for SARS-CoV-2 entry, is a key antiviral target. Here, we computationally profiled the TMPRSS2-binding affinities of 15 antiviral compounds. Molecular dynamics (MD) simulations for the docked complexes revealed that three compounds exited the substrate-binding cavity (SBC), suggesting noncompetitive inhibition.
View Article and Find Full Text PDFTranscriptomic Profile Analysis of Brain Tissue in the Absence of Functional TRPM8 Calcium Channel.
Biomedicines
December 2024
Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
Transient Receptor Potential Melastatin 8 (TRPM8) is a non-selective, Ca-permeable cation channel involved in thermoregulation and other physiological processes, such as basal tear secretion, cell differentiation, and insulin homeostasis. The activation and deactivation of TRPM8 occur through genetic modifications, channel interactions, and signaling cascades. Recent evidence suggests a significant role of TRPM8 in the hypothalamus and amygdala related to pain sensation and sexual behavior.
View Article and Find Full Text PDFLewis Base-Enhanced C-H Bond Functionalization Mediated by a Diiron Imido Complex.
Inorg Chem
January 2025
Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061, United States.
Herein, we investigate the effects of ligand design on the nuclearity and reactivity of metal-ligand multiply bonded (MLMB) complexes to access an exclusively bimetallic reaction pathway for C-H bond functionalization. To this end, the diiron alkoxide [Fe(Dbf)] () was treated with 3,5-bis(trifluoromethyl)phenyl azide to access the diiron imido complex [Fe(Dbf)(μ-NCHF)] () that promotes hydrogen atom abstraction (HAA) from a variety of C-H and O-H bond containing substrates. A diiron bis(amide) complex [Fe(Dbf)(μ-NHCHF)(NHCHF)] () was generated, prompting the isolation of the analogous bridging amide terminal alkoxide [Fe(Dbf)(μ-NHCHF)(OCH)] () and the asymmetric pyridine-bound diiron imido [Fe(Dbf)(μ-NCHF)(NCH)] ().
View Article and Find Full Text PDFDetection of reproducible liver cancer specific ligand-receptor signaling in blood.
Front Bioinform
January 2025
RNA Bioinformatics and High Throughput Analysis, Friedrich Schiller University Jena, Jena, Germany.
Cell-cell communication mediated by ligand-receptor interactions (LRI) is critical to coordinating diverse biological processes in homeostasis and disease. Lately, our understanding of these processes has greatly expanded through the inference of cellular communication, utilizing RNA extracted from bulk tissue or individual cells. Considering the challenge of obtaining tissue biopsies for these approaches, we considered the potential of studying cell-free RNA obtained from blood.
View Article and Find Full Text PDFLutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.
EJNMMI Radiopharm Chem
January 2025
Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, 52750, Mexico.
Background: Cancer immunotherapy is a relatively new approach to cancer treatment. Peptides that target specific pathways and cells involved in immunomodulation can potentially improve the efficacy of cancer therapy. Recently, we reported iPD-L1 as a novel inhibitor peptide that specifically targets the cancer cell ligand PD-L1 (programmed death ligand 1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!